FR23C1001I2 - Composition de facteur vii - Google Patents

Composition de facteur vii

Info

Publication number
FR23C1001I2
FR23C1001I2 FR23C1001C FR23C1001C FR23C1001I2 FR 23C1001 I2 FR23C1001 I2 FR 23C1001I2 FR 23C1001 C FR23C1001 C FR 23C1001C FR 23C1001 C FR23C1001 C FR 23C1001C FR 23C1001 I2 FR23C1001 I2 FR 23C1001I2
Authority
FR
France
Prior art keywords
composition
factor vii
vii
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1001C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of FR23C1001I1 publication Critical patent/FR23C1001I1/fr
Application granted granted Critical
Publication of FR23C1001I2 publication Critical patent/FR23C1001I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR23C1001C 2009-06-26 2023-01-10 Composition de facteur vii Active FR23C1001I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0954390A FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii
PCT/FR2010/051229 WO2010149907A1 (fr) 2009-06-26 2010-06-18 Composition de facteur vii
EP10734272.7A EP2445516B1 (fr) 2009-06-26 2010-06-18 Composition de facteur vii

Publications (2)

Publication Number Publication Date
FR23C1001I1 FR23C1001I1 (fr) 2023-03-10
FR23C1001I2 true FR23C1001I2 (fr) 2025-03-28

Family

ID=41620211

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0954390A Active FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii
FR23C1001C Active FR23C1001I2 (fr) 2009-06-26 2023-01-10 Composition de facteur vii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0954390A Active FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii

Country Status (17)

Country Link
US (3) US9029316B2 (fr)
EP (2) EP2985033B3 (fr)
JP (3) JP5706888B2 (fr)
KR (1) KR101468115B1 (fr)
CN (2) CN105106943A (fr)
AR (1) AR077234A1 (fr)
AU (1) AU2010264369B2 (fr)
BR (1) BRPI1010707A2 (fr)
CA (1) CA2764779C (fr)
DK (2) DK2445516T3 (fr)
ES (2) ES2550269T3 (fr)
FR (2) FR2947181B1 (fr)
IL (1) IL216872A (fr)
NL (1) NL301213I2 (fr)
PL (2) PL2445516T3 (fr)
TR (1) TR201906145T4 (fr)
WO (1) WO2010149907A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106916802B (zh) 2003-12-01 2022-03-25 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
SG191781A1 (en) 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
EP2687595B1 (fr) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Procédé de purification de facteur VII transgénique
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
WO2016198641A1 (fr) 2015-06-12 2016-12-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition injectable de facteur vii et d'excipients
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
HUE064463T2 (hu) * 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
WO2021030787A1 (fr) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée et un traitement à la demande
CN117860874B (zh) * 2024-03-12 2024-07-02 正大天晴药业集团南京顺欣制药有限公司 重组人凝血因子VIIa的药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
JP3543144B2 (ja) * 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
JP2003507388A (ja) 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
AU2001254624A1 (en) * 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
AU2004264282B2 (en) * 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
JP2008531525A (ja) * 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド製剤を安定化する化合物
RU2440810C2 (ru) * 2005-04-28 2012-01-27 Ново Нордиск Хелс Кеа Аг Закрытый контейнер, содержащий активированный полипептид фактора vii, способы его получения и набор и способ применения набора
US20090017007A1 (en) * 2005-08-26 2009-01-15 Maxygen Holdings Ltd. Liquid factor vii composition
FR2894831B1 (fr) * 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
EP2114379A2 (fr) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Compositions de facteur vii et viia
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
EP2129686B1 (fr) * 2007-03-20 2016-07-13 CSL Behring GmbH Procédés pour la production à l'échelle industrielle de préparations thérapeutiques du facteur h du complément pour le plasma humain
EP2152233A1 (fr) * 2007-05-02 2010-02-17 Novo Nordisk Health Care AG Formulations à concentration élevée de polypeptidiques du facteur vii comprenant un préservateur aromatique et un antioxydant
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii

Also Published As

Publication number Publication date
DK2985033T6 (da) 2022-11-07
PL2445516T3 (pl) 2015-12-31
ES2725449T3 (es) 2019-09-24
DK2445516T3 (en) 2015-10-19
US20160271233A1 (en) 2016-09-22
NL301213I1 (fr) 2023-01-18
JP2017081978A (ja) 2017-05-18
JP2012530770A (ja) 2012-12-06
CA2764779A1 (fr) 2010-12-29
FR2947181B1 (fr) 2012-05-04
US9029316B2 (en) 2015-05-12
PL2985033T3 (pl) 2019-08-30
BRPI1010707A2 (pt) 2016-03-15
JP2015134795A (ja) 2015-07-27
CA2764779C (fr) 2015-09-29
IL216872A (en) 2017-07-31
EP2985033B3 (fr) 2022-10-26
JP5706888B2 (ja) 2015-04-22
NL301213I2 (nl) 2023-12-14
CN102458455B (zh) 2015-04-08
TR201906145T4 (tr) 2019-05-21
CN102458455A (zh) 2012-05-16
US20150216951A1 (en) 2015-08-06
US9358275B2 (en) 2016-06-07
EP2985033B1 (fr) 2019-03-20
FR2947181A1 (fr) 2010-12-31
ES2550269T3 (es) 2015-11-05
AR077234A1 (es) 2011-08-10
IL216872A0 (en) 2012-02-29
US20120087908A1 (en) 2012-04-12
EP2445516A1 (fr) 2012-05-02
KR20120047918A (ko) 2012-05-14
KR101468115B1 (ko) 2014-12-03
DK2985033T3 (da) 2019-06-17
CN105106943A (zh) 2015-12-02
AU2010264369A1 (en) 2012-01-19
EP2985033A1 (fr) 2016-02-17
AU2010264369B2 (en) 2013-06-27
ES2725449T7 (es) 2022-12-20
WO2010149907A1 (fr) 2010-12-29
EP2445516B1 (fr) 2015-08-12
US9968662B2 (en) 2018-05-15
FR23C1001I1 (fr) 2023-03-10

Similar Documents

Publication Publication Date Title
FR23C1001I1 (fr) Composition de facteur vii
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
ME03475B (fr) Compositions antiparasitaires comprenant dihydroazoles
EP2515946A4 (fr) Nanoconjugués et compositions de nanoconjugués
BRPI1015474A2 (pt) composição
FR2942627B1 (fr) Composition de graisse
EP2488022A4 (fr) Compositions
EP2675909A4 (fr) Composition de glucosylstevia
BR112012005237A2 (pt) utilização de composições ternárias
EP2720561A4 (fr) Composition de stévia
BRPI1013335A2 (pt) composição compósita
EP2470605A4 (fr) Compositions durcies de polyhydroxyalcanoate
EP2713762A4 (fr) Composition de stévia
UY33161A (es) Composiciones plaguicidas
DOP2011000396A (es) Composiciones novedosas
BRPI1010690A2 (pt) composições
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
FI20096144A0 (fi) Ulkovalaisu
EP2429699A4 (fr) Modification de la densité
EP2474324A4 (fr) Composition de revêtement
PT2635269T (pt) Composição de combinação
EP2494966A4 (fr) Composition stable de rasagiline
DK2453858T3 (da) Fremgangsmåde
PT2492266E (pt) Derivado de 5-hidroxipirimidino-4-carboxamida